Search
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022. … [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … [L40313] In November 2022, the FDA updated the Health Care Provider Fact Sheet for bebtelovimab to inform of its expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2.
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. … Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedApproved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [ribavirin] depending on the level of liver damage or cirrhosis [FDA Label]. … Treatment with direct acting antivirals such as ledipasvir is associated with very minimal side effects, with the most common being headache and fatigue [FDA Label].
Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalTelmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinit...
Mixtures: Nra-telmisartan/hctz, Nra-telmisartan/hctzProducts: Nra-telmisartanFutibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigational[A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Calcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedBy FDA, calcium glycerophosphate is considered a generally recognized as safe (GRAS) food ingredient as a nutrient supplement (source of calcium or phosphorus), or in food products such as gelatins, puddings
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Tamsulosin
go.drugbank.com/drugs/DB00706ApprovedInvestigational[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]